{"id":"tak-625","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"5-10%","effect":"Vomiting"},{"rate":"5-10%","effect":"Diarrhea"},{"rate":"5-10%","effect":"Abdominal pain"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"TAK-625 works by mimicking the action of the natural hormone GLP-1, which helps to lower blood sugar levels by enhancing glucose-dependent insulin secretion, suppressing inappropriately elevated glucagon secretion, and slowing gastric emptying.","oneSentence":"TAK-625 is a glucagon-like peptide-1 (GLP-1) receptor agonist.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:37:26.229Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes"}]},"trialDetails":[{"nctId":"NCT07293897","phase":"","title":"A Database Study of Maralixibat (TAK-625) in Participants With Alagille Syndrome (ALGS) and Progressive Familial Intrahepatic Cholestasis (PFIC)","status":"RECRUITING","sponsor":"Takeda","startDate":"2026-01-13","conditions":"Alagille Syndrome (ALGS), Progressive Familial Intrahepatic Cholestasis (PFIC)","enrollment":50},{"nctId":"NCT05543174","phase":"PHASE3","title":"A Study of TAK-625 for the Treatment of Alagille Syndrome (ALGS)","status":"COMPLETED","sponsor":"Takeda","startDate":"2023-01-16","conditions":"Alagille Syndrome (ALGS)","enrollment":7},{"nctId":"NCT05543187","phase":"PHASE3","title":"A Study of TAK-625 for the Treatment of Progressive Familial Intrahepatic Cholestasis (PFIC)","status":"COMPLETED","sponsor":"Takeda","startDate":"2023-01-10","conditions":"Progressive Familial Intrahepatic Cholestasis (PFIC)","enrollment":5}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Maralixibat chloride"],"phase":"phase_3","status":"active","brandName":"TAK-625","genericName":"TAK-625","companyName":"Takeda","companyId":"takeda","modality":"Small molecule","firstApprovalDate":"","aiSummary":"TAK-625 is a glucagon-like peptide-1 (GLP-1) receptor agonist. Used for Type 2 diabetes.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}